

**Table S2 Comparison of demographic data among each PM/DM subtype in PM/DM-ILD patients.**

PM/DM-ILD ( <i>n</i> = 116)	PM ( <i>n</i> = 22)	DM ( <i>n</i> = 51)	CADM ( <i>n</i> = 43)	<i>p</i> -Value	
Women <i>n</i> (%)	13 /22 (59.1%)	40 /51 (78.4%)	30 /43 (69.8%)	0.23	
Age (year)	56.2 ± 14.9 <sup>a</sup>	60.0 ± 13.3 <sup>a</sup>	51.3 ± 15.4 <sup>a</sup>	0.016**	
Smoking <i>n</i> (%)	10 /21 (47.6%)	13 /47 (27.7%)	14 /38 (36.8%)	0.27	
Follow-up period (months)	57.9 [48.4-78.7] <sup>b</sup>	42.4 [18.8-69.0] <sup>b</sup>	39.5 [14.5-80.0] <sup>b</sup>	0.081	
Baseline data	CK (U/l)	1,956 [1,067-4,399] <sup>b</sup>	609 [211-1,773] <sup>b</sup>	83 [57-183] <sup>b</sup>	<0.001**
	LDH (U/l)	449 [374-564] <sup>b</sup>	437 [341-590] <sup>b</sup>	284 [242-343] <sup>b</sup>	<0.001**
	KL-6 (U/ml)	685 [490-1,709] <sup>b</sup>	759 [463-1,129] <sup>b</sup>	657 [413-911] <sup>b</sup>	0.35
	CRP (mg/dl)	0.71 [0.18-1.95] <sup>b</sup>	0.62 [0.16-1.94] <sup>b</sup>	0.49 [0.15-1.32] <sup>b</sup>	0.44
	Lymphocyte (/μl)	1,346 [983-1,553] <sup>b</sup>	971 [696-1,386] <sup>b</sup>	825 [592-1,041] <sup>b</sup>	0.022*
	Albumin (g/dl)	3.42 ± 0.49 <sup>a</sup>	3.32 ± 0.61 <sup>a</sup>	3.55 ± 0.51 <sup>a</sup>	0.16
	PaCO <sub>2</sub> (mmHg)	39.3 [38.2-41.8] <sup>b</sup>	37.0 [34.0-39.5] <sup>b</sup>	36.4 [34.1-39.9] <sup>b</sup>	0.14
	Ferritin (ng/ml)	258 [165-305] <sup>b</sup>	960 [719-1,365] <sup>b</sup>	361 [116-645] <sup>b</sup>	0.032*
	IgG (mg/dl)	1,580 [1,341-2,285] <sup>b</sup>	1,444 [1,221-1,731] <sup>b</sup>	1,489 [1,358-1,811] <sup>b</sup>	0.44
	Autoantibody <i>n</i> (%)	Anti-Jo-1 Ab	8 /21 (38.1%)	10 /51 (19.6%)	3 /42 (7.1%)
Anti-ARS Ab		1 /2 (50.0%)	3 /21 (14.3%)	5 /22 (22.7%)	NA <sup>d</sup>
Anti-MDA5 Ab		0 /1 (0%)	4 /17 (23.5%)	4 /13 (30.8%)	NA <sup>d</sup>
Anti-TIF-1γ Ab		0 /0 (0%)	2 /2 (100%)	0 /0 (100%)	NA <sup>d</sup>
ANA (>80×)		3 /20 (15.0%)	22 /48 (45.8%)	8 /43 (18.6%)	0.005**
Anti-SS-A Ab		3 /14 (21.4%)	8 /36 (22.2%)	4 /30 (13.3%)	0.63
Malignancy (<3 years) <i>n</i> (%)	3 /20 (15.0%)	12 /49 (24.5%)	6 /43 (14.0%)	0.39	
HRCT	Zone A	1.0 [0-1.0] <sup>b</sup>	1.0 [0-1.0] <sup>b</sup>	1.0 [0-1.0] <sup>b</sup>	0.90
	Zone B	1.0 [1.0-1.8] <sup>b</sup>	1.0 [0-2.0] <sup>b</sup>	1.0 [0-1.0] <sup>b</sup>	0.58
	Zone C	2.0 [1.3-3.0] <sup>b</sup>	1.0 [1.0-3.0] <sup>b</sup>	1.0 [1.0-2.0] <sup>b</sup>	0.22
	Zone D	4.0 [3.0-4.8] <sup>b</sup>	3.0 [2.0-4.0] <sup>b</sup>	3.0 [2.0-3.0] <sup>b</sup>	0.033*
	Zone total	8.0 [5.3-10.8] <sup>b</sup>	6.0 [3.0-10.0] <sup>b</sup>	6.0 [4.0-7.0] <sup>b</sup>	0.25
Treatment	Initial PSL dose (mg/kg/day)	0.77 ± 0.25 <sup>a</sup>	0.92 ± 0.28 <sup>a</sup>	0.72 ± 0.32 <sup>a</sup>	0.004**
	mPSL pulse <i>n</i> (%)	10 /22 (45.5%)	35 /51 (68.6%)	32 /43 (74.4%)	0.059
	IVCY <i>n</i> (%)	6 /22 (27.3%)	19 /51 (37.3%)	23 /43 (53.5%)	0.092
	Calcineurin inhibitor <i>n</i> (%)	8 /22 (36.4%)	36 /50 (72.0%)	37 /43 (86.0%)	<0.001**
	Combination therapy <sup>c</sup> <i>n</i> (%)	2 /22 (9.1%)	18 /51 (35.3%)	20 /43 (46.5%)	0.011*
	IVIg <i>n</i> (%)	1 /22 (4.5%)	10 /50 (20.0%)	2 /43 (4.7%)	NA <sup>d</sup>
Prognosis	Death <i>n</i> (%)	6 /22 (27.3%)	15 /51 (29.4%)	7 /43 (9.6%)	0.31
	ICU management <i>n</i> (%)	2 /22 (9.1%)	7 /51 (13.7%)	4 /43 (9.3%)	NA <sup>d</sup>

<sup>a</sup> The data are shown as the mean ± standard deviation.

<sup>b</sup> Values are the median [interquartile range].

<sup>c</sup> Combination therapy includes glucocorticoid, IVCY and calcineurin inhibitors.

<sup>d</sup> Not applicable.

\**p* < 0.05, \*\**p* < 0.01.